Document:

EX-10.21

 Exhibit 10.21 
  

					
		 	 Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Double asterisks denote omissions.
	  	

 June 7, 2018 

Shire Human Genetics Therapies, Inc. 
 300 Shire Way 

Lexington, MA 02421 
 Attn: General Counsel 

 

	Re:	First Amendment to Asset Purchase Agreement dated December 22, 2016 

 Dear Clare, 

Reference is made to the Asset Purchase Agreement by and between Translate Bio, Inc. formerly known as RaNA Therapeutics, Inc.
(“Translate Bio”) and Shire Human Genetics Therapies, Inc. (“Shire”) entered into as of December 22, 2016 (the “Agreement”). Capitalized terms used but not defined herein have the respective
meanings set forth in the Agreement. 
 Translate Bio is in the process of negotiating a license agreement with Sanofi Pasteur (as may be
amended from time to time, the “License Agreement”) under which an Affiliate of Translate Bio will grant a license to Sanofi Pasteur under the Transferred Patents to develop and commercialize vaccines to prevent or treat human viral
infectious disease pathogens in the Licensed Fields (as defined below). Shire recognizes that by aligning the terms of the Agreement with the potential License Agreement, Shire will be more likely to receive
Earn-Out Payments and other amounts under the Agreement. Therefore, Shire is willing to enter into this letter amendment relating to vaccines in the Licensed Fields under the License Agreement. 

Through this letter amendment to the Agreement, Shire and Translate Bio hereby agree to amend the Agreement, as follows, provided that such
amendments automatically become effective only upon the closing or consummation of the License Agreement (the “Amendment Effective Date”): 

1.    As of the Amendment Effective Date and solely with respect to the License Agreement, the following new definitions
are hereby added to Article VII as follows: 
 “License Agreement” means that certain license agreement
between Buyer and Sanofi Pasteur. 

 June 7, 2018 First Amendment 

 Page
 2
 of 5 
  

 “Licensed Field” means each of the following viral
infectious disease pathogens: (a) three (3) identified pathogens selected by Sanofi Pasteur, and (b) two (2) other human viral infectious disease pathogens as determined in accordance with the License Agreement; and in each case as
promptly identified in writing by Buyer to Seller. Until such time as the identity of any such pathogen in the Licensed Field is publicly known, Seller agrees to treat the identify of such pathogen confidentially, and will disclose such identity
only to such employees of Seller or its Affiliates who reasonably need to know such information in connection with financial and accounting matters or in connection with prosecuting, defending, or settling any litigation, performing obligations
under this Agreement or other proper business purposes (including determining any matter relating to its rights and obligations hereunder). 

“MRT Vaccine Product” means an MRT Product that (a) is a vaccine for the prevention, palliation,
treatment, or cure of a disease, disorder or condition caused by an infectious disease pathogen in a Licensed Field, and (b) includes or comprises an MRT Compound having a sequence that encodes a protein that is from, or that binds to, such
infectious disease pathogen; provided that in no event shall an MRT Vaccine Product be a product that includes mRNA encoding an antibody. 

2.    As of the Amendment Effective Date and solely with respect to the License Agreement, Section 1.11(a)(ii) is
hereby deleted and replaced with the following: 
 (ii)    With respect to each Non-CFTR MRT Product, a one-time payment of Ten Million Dollars ($10,000,000) upon the First Commercial Sale of such Non-CFTR MRT
Product [**], provided, however, that the Milestone Payment in this Section 1.11(a)(ii) shall be due no more than once with respect to any two Non-CFTR MRT Products
(that are not MRT Vaccine Products) if all of the MRT Compound(s) in one of the Non-CFTR MRT Products are the same as all of the MRT Compound(s) in the other Non-CFTR
MRT Product (it being understood that, for purposes of this Section 1.11(a)(ii), (A) any metabolite, prodrug, hydrate or other solvate, analog, ester, salt, intermediate, stereoisomer, racemate, tautomer or polymorph of any
MRT Compound shall be considered the same MRT Compound, and (B) any MRT Compound containing a different sequence than (e.g., an optimized sequence of) any other MRT Compound shall be considered a different MRT Compound from such other MRT
Compound), regardless of whether such MRT Products containing such MRT Compound(s) have different strengths, formulations, dosage forms or modes of administration or are marketed and sold for different Indications; and provided,
further, that the Milestone Payment in this Section 1.11(a)(ii) shall be due no more than once with respect to any MRT Vaccine Product in the same Licensed Field; 

 June 7, 2018 First Amendment 

 Page
 3
 of 5 
  

 3.    As of the Amendment Effective Date and solely with respect to the
License Agreement, Section 1.11(a)(iii) is hereby deleted and replaced with the following: 

(iii)    A one-time payment of [**] Dollars ($[**]) upon the first
achievement of the aggregate Annual Net Sales of any MRT Product equaling or being greater than [**] Dollars ($[**]), provided, however, that the Annual Net Sales of any two or more MRT Products (that are not MRT Vaccine Products) may
be aggregated to determine whether the Milestone Event in this Section 1.11(a)(iii) has been achieved only if all of the MRT Compound(s) in one of the MRT Products are the same as all of the MRT Compound(s) in the other MRT
Product(s) (it being understood that, for purposes of this Section 1.11(a)(iii), (A) any metabolite, prodrug, hydrate or other solvate, analog, ester, salt, intermediate, stereoisomer, racemate, tautomer or polymorph of any
MRT Compound shall be considered the same MRT Compound and (B) any MRT Compound containing a different sequence than (e.g., an optimized sequence of) any other MRT Compound shall be considered a different MRT Compound from such other MRT
Compound), regardless of whether such MRT Products have different strengths, formulations, dosage forms or modes of administration or are marketed and sold for different Indications; and provided, further, that the Annual Net Sales of
any two or more MRT Vaccine Products may be aggregated to determine whether the Milestone Event in this Section 1.11(a)(iii) has been achieved only if the MRT Vaccine Products are in the same Licensed Field; and 

4.    As of the Amendment Effective Date and solely with respect to the License Agreement, a new
Section 1.11(c)(iii) is hereby added as follows: 
 (iii)     With respect to
the calculation of Earn-Out Payments arising from the sale of each MRT Product and the determination of the applicable Earn-Out Period for each such MRT Product, any MRT
Product that includes or comprises an MRT Compound containing a different sequence than any MRT Compound in any other MRT Product shall be considered a different MRT Product, regardless of whether the MRT Product including or comprising the MRT
Compound containing the different sequence is an MRT Vaccine Product. 
 5.    As of the Amendment Effective Date and
solely with respect to the License Agreement, the following new language is hereby added to the end of the Net Sales definition in Article VII and used in the calculation of Net Sales of MRT Vaccine Products: 

If an MRT Vaccine Product is sold as a product intended for more than one disease indication, containing such MRT Vaccine Product in
combination with one or more other active ingredients or products that are not MRT Vaccine Products in any country in any calendar quarter (a “Combination Product”), the Net Sales of the MRT Vaccine Product shall be determined as
follows: 
 (i)    Net Sales of the MRT Vaccine Product shall be determined by multiplying the Net Sales (as defined
above) of the Combination Product by the fraction A / (A+B) where A is the known average sale price in such country of the MRT Vaccine Product when sold separately in finished form in such calendar quarter, and B is the known average sale price in
that country of the other active ingredient(s) or product(s) when sold separately in finished form in such calendar quarter; and 

 June 7, 2018 First Amendment 

 Page
 4
 of 5 
  

 (ii)    If such average sale price cannot be determined for the MRT
Vaccine Product and/or the other ingredient(s) or product(s) in the Combination Product in any country in any calendar quarter, Net Sales for the MRT Vaccine Product in such country and calendar quarter shall be calculated as mutually agreed by the
Parties and based on the fraction of the total number of pathogens for which the Combination Product includes at least one vaccine; provided that in no event shall Net Sales for the MRT Vaccine Product be less than [**]% of Net Sales of the
Combination Product, regardless of the number of other active ingredient(s) or product(s) in the Combination Product. 
 Except as provided
herein, the Agreement shall remain in full force and effect without any amendments or modifications. For clarity, the amendments set forth herein shall not apply to any agreement between Translate Bio and a third party other than the License
Agreement and shall only apply to MRT Vaccine Products under the License Agreement. After the date set forth below, every reference in the Agreement to the “Agreement” shall mean the Agreement as amended by this letter amendment. This
letter amendment may be executed by Shire and Translate Bio in multiple counterparts which may be delivered by facsimile transmission, by digital signature or by a scanned signature page in a format such as, without limitation, PDF. Each counterpart
when so executed and delivered shall be deemed an original, and all such counterparts taken together shall constitute one and the same instrument. This letter amendment shall be effective as of the date of the last signature below. 

[Signature Page Follows] 

 June 7, 2018 First Amendment 

 Page
 5
 of 5 
  

 If the above reflects your understanding of the amendment to the Agreement, please
acknowledge your agreement of the foregoing by executing the countersignature below. 
  

			
	Very truly yours,
	
	 /s/ Ronald Renaud

	Name:	 	Ronald Renaud
	Title:	 	CEO
	Date:	 	6/8/2018

 AGREED & ACCEPTED 

SHIRE HUMAN GENETIC THERAPIES, INC. 
  

			
	 /s/ Clare Fisher

	Name:	 	Clare Fisher
	Title:	 	GVP, Transactions
	Date:	 	6/7/2018EX-4.2

 Exhibit 4.2 
  

BLOOM ENERGY CORPORATION 
  

 
 EIGHTH
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT 
  

 
 June 30, 2011

  
  
  

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	1.	  	Certain Definitions	  	 	2	 
	2.	  	Restrictions on Transferability	  	 	3	 
	3.	  	Notice of Proposed Transfers	  	 	3	 
	4.	  	Requested Registration	  	 	4	 
	5.	  	Company Registration	  	 	6	 
	6.	  	Registration on Form S-3	  	 	8	 
	7.	  	Expenses of Registration	  	 	9	 
	8.	  	Registration Procedures	  	 	9	 
	9.	  	Termination of Registration Rights	  	 	10	 
	10.	  	Lock-up Agreement	  	 	10	 
	11.	  	Restrictive Legend	  	 	11	 
	12.	  	Indemnification	  	 	12	 
	13.	  	Information by Holder	  	 	14	 
	14.	  	Rule 144 Reporting	  	 	14	 
	15.	  	Transfer of Rights	  	 	15	 
	16.	  	Governing Law	  	 	15	 
	17.	  	Entire Agreement	  	 	15	 
	18.	  	Notices	  	 	15	 
	19.	  	Amendment	  	 	15	 
	20.	  	Limitations on Subsequent Registration Rights	  	 	16	 
	21.	  	Aggregation	  	 	17	 
	22.	  	Counterparts	  	 	17	 
	23.	  	Telecopy Execution and Delivery	  	 	17	 
	24.	  	Jurisdiction; Venue	  	 	17	 
	25.	  	Waiver of Potential Conflicts of Interest	  	 	17	 
	26.	  	Adjustments for Stock Splits, Etc	  	 	17	 
	27.	  	Costs And Attorneys’ Fees	  	 	18	 
	28.	  	Amendment and Restatement	  	 	18	 

  
 - i - 

 BLOOM ENERGY CORPORATION 

EIGHTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT 

This Eighth Amended and Restated Registration Rights Agreement (this “Agreement”) is made as of June 30, 2011, by and among
Bloom Energy Corporation, a Delaware corporation (the “Company”), and each of the persons and entities who have purchased shares of the Company’s Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock,
Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock or Series G Preferred Stock pursuant to stock purchase agreements between such purchasers and the Company. 

This Agreement amends and restates in its entirety the Seventh Amended and Restated Registration Rights Agreement dated as of October 29,
2010 (the “Prior Registration Agreement”). 
 Recitals 

WHEREAS, the Company proposes to sell and issue shares of its Series G Preferred Stock to certain investors pursuant to a Series G Preferred
Stock Purchase Agreement dated on or after the date herewith; 
 WHEREAS, such investors have required, as a condition to their purchase of
such Series G Preferred Stock, that the Company grant registration rights on the terms and conditions set forth herein such that the purchasers of the Series G Preferred Stock shall enjoy registration rights that are pari passu with those
held by the holders of currently outstanding Registrable Securities (the “Current Rights Holders”); 

WHEREAS, Section 20 of the Prior Registration Agreement prevents the grant of registration rights by the
Company unless such rights are subordinate to those held by the Current Rights Holders; 
 WHEREAS, Section 19 of the Prior Registration
Agreement permits the amendment of the Prior Registration Agreement with the written consent of the Company and holders of a majority of the then outstanding shares of Registrable Securities; and 

WHEREAS, the Company and holders of at least a majority of the currently outstanding Registrable Securities who are party to the Prior
Registration Agreement wish to amend and restate the Prior Registration Agreement on the terms and conditions set forth herein in order to grant pari passu registration rights to the purchasers of the Company’s Series G Preferred Stock;

 Agreement 

NOW, THEREFORE, in consideration of the foregoing, the parties agree as follows: 

1. Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 

“Commission” shall mean the United States Securities and Exchange Commission or any successor agency. 

“Common Stock” shall mean shares of the Company’s Common Stock. 

“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 

“Holder” shall mean each Purchaser, and any transferee of Registrable Securities who pursuant to Section 15 below is entitled
to registration rights hereunder. 
 “Preferred” shall mean any series of Preferred Stock of the Company (a) issued and
sold by the Company pursuant to a stock purchase agreement approved by the Board or (b) issued upon exercise of any outstanding security exercisable for shares of any series of the Company’s Preferred Stock, if the issuance of such security was
approved by the Board. 
 “Purchaser” shall mean each person or entity who has (a) acquired shares of Preferred and who is
a signatory to this Agreement, or (b) acquires securities of the Company in the future pursuant to an agreement with the Company and becomes a party to this Agreement pursuant to Section 20(b) hereof. 

“Registrable Securities” shall mean (a) shares of the Common Stock issued or issuable upon the conversion of the Preferred;
(b) any Common Stock issued or issuable in respect of shares of the Preferred; (c) shares of Common Stock issued or issuable upon any conversion of the Preferred upon any stock split, stock dividend, recapitalization or similar event; (d) shares of
Common Stock issued or issuable upon the exercise of the Series E Warrants; and (e) any shares of Common Stock and any shares of Common Stock issued or issuable upon conversion or exercise of any convertible security for which subsequent
registration rights are granted in accordance with Section 20(b) below; provided, however, that Registrable Securities shall not include any securities that have been (i) sold to or through a broker or dealer or underwriter in a public
distribution or public securities transaction, (ii) sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act under Section 4(1) thereof so that all transfer restrictions and restrictive legends
with respect thereto, if any, are removed upon the consummation of such sale, or (iii) sold by a person in a transaction in which rights under this Agreement are not assigned. 

The terms “register,” “registered” and “registration” refer to a registration effected by
preparing and filing a registration statement in compliance with the Securities Act and the declaration or ordering of the effectiveness of such registration statement. 

  
 -2- 

 “Registration Expenses” shall mean all expenses incurred by
the Company in complying with Sections 4, 5, and 6 hereof, including, without limitation, all registration, qualification and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company,
reasonable fees and disbursements of one special counsel to the Holders, blue sky fees and expenses, and the expense of any special audits incident to or required by any such registration, but excluding all Selling Expenses. 

“Restricted Securities” shall mean the securities of the Company required to bear the legend set forth in Section 11 hereof
(or any similar legend). 
 “Securities Act” shall mean the Securities Act of 1933, as amended. 

“Selling Expenses” shall mean all underwriting discounts, selling commissions, and stock transfer taxes applicable to the
securities registered by the Holders and any fees of counsel to any Holder (other than as allowed as a Registration Expense). 

“Series E Warrants” shall mean the warrants issued pursuant to the Series E Preferred Stock Purchase Agreement dated November
2, 2007, by and among the Company and the investors listed on Exhibits A-1 and A-2 attached thereto. 
 2. Restrictions on
Transferability. The Restricted Securities shall not be transferable except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. Each Holder of
Restricted Securities will cause any proposed transferee of the Restricted Securities held by such Holder to agree to take and hold such Restricted Securities subject to the provisions and upon the conditions specified in this Agreement. 

3. Notice of Proposed Transfers. The Holder of each certificate representing Restricted Securities by acceptance thereof agrees to
comply in all respects with the provisions of this Section 3. Prior to any proposed transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transfer, the Holder
thereof shall give written notice to the Company of such Holder’s intention to effect such transfer. Each such notice shall describe the manner and circumstances of the proposed transfer in sufficient detail, and shall, if the Company so
reasonably requests, be accompanied by either (a) a written opinion of legal counsel, who shall be reasonably satisfactory to the Company, addressed to the Company and reasonably satisfactory in form and substance to the Company’s counsel,
to the effect that the proposed transfer of the Restricted Securities may be effected without registration under the Securities Act, or (b) a “no action” letter from the Commission to the effect that the transfer of such securities without
registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto, whereupon the Holder of such Restricted Securities shall be entitled to transfer such Restricted Securities in accordance with
the terms of the notice delivered by such Holder to the Company; provided, however, that (i) no opinion or “no action” letter shall be required in connection with any transfer pursuant to Rule 144 promulgated under the
Securities Act, except for such customary legal opinions as may be required by the Company’s transfer agent and (ii) no opinion or “no action” letter need be obtained with respect to a transfer if no consideration is paid in
connection to such transfer and the transfer is to (i) an “Affiliate” of a Holder of Restricted 

  
 -3- 

 
Securities (as such term is defined in Rule 144(a) promulgated under the Securities Act (which for purposes of this Agreement shall be deemed to include a partner, active or retired, of a Holder
and shall include any investment entity under common management with a Holder), (ii) the estate of any such Holder, (iii) the spouse, children, grandchildren or spouse of such children or grandchildren of any Holder or to trusts for the benefit of
any Holder or such persons, (iv) to the partners or retired partners of a Holder that is a partnership in accordance with partnership interests, (v) to the shareholders, officers, directors or employees of a Holder that is a corporation in
accordance with the terms of their employment or their interest in such corporation, (vi) to the members or former members of a Holder that is a limited liability company in accordance with their interest in such limited liability company. Each
certificate evidencing the Restricted Securities transferred as above provided shall bear the appropriate restrictive legends described in Section 11 hereof, except that such certificate shall not bear any such restrictive legend if in the
reasonable opinion of counsel for the Company such legend is not required. 
 4. Requested Registration. Request for
Registration. If, at any time after the first to occur of (i) June     , 2016, or (ii) the expiration of six months following the Company’s initial registered public offering, the Company shall receive from any
Holder or group of Holders of Registrable Securities representing not less than 33% of the Registrable Securities then outstanding, a written request that the Company effect any registration, qualification or compliance with respect to all or a part
of the Registrable Securities, the anticipated gross offering price of which would exceed $10,000,000, the Company will: 
 (x) promptly
give written notice of the proposed registration, qualification, or compliance to all other Holders; and 
 (y) as soon as practicable, use
its best efforts to effect within 120 days of the receipt of such request such registration, qualification or compliance (including, without limitation, the execution of an undertaking to file post-effective amendments, appropriate qualification
under applicable blue sky or other state securities laws, and appropriate compliance with applicable regulations issued under the Securities Act and any other governmental requirements or regulations) as may be so requested and as would permit or
facilitate the sale and distribution of all or any such portion of such Registrable Securities as are specified in such request, together with all or any such portion of the Registrable Securities of any Holder or Holders joining in such request as
are specified in a written request received by the Company within 20 days after receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to take any action to effect any such
registration, qualification or compliance pursuant to this Section 4: 
 (A) in any particular jurisdiction in which the Company would be
required to execute a general consent to service of process in effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

  
 -4- 

 (B) prior to 60 days immediately following the effective date of any registration statement
pertaining to securities of the Company (other than a registration of securities pursuant to Rule 145 promulgated under the Securities Act or with respect to an employee benefit plan); provided, however, that with respect to the
Company’s initial registered public offering, such period will be the market stand-off period specified in the agreements contemplated by Section 10 below; 

(C) prior to the time the Company abandons its efforts to effect its initial registered public offering if the Company has delivered written
notice to the Holders within 30 days of receiving a registration request under this Section 4 that the Company intends to effect such an initial registered public offering and intends to file for such offering within 90 days; provided
that the Company is actively employing in good faith all commercially reasonable efforts to cause such registration statement to become effective; or 

(D) after the Company has effected two such registrations pursuant to this Section 4, and such registrations have been declared or ordered
effective. 
 The Company shall not be required to maintain and keep any such registration under this Section 4 effective after the
earlier to occur of (i) 90 days from the date of effectiveness of such registration statement or (ii) such date as the disposition of the Registrable Securities subject to such registration has been completed. 

Subject to the foregoing clauses, the Company shall file a registration statement covering the Registrable Securities so requested to be
registered as soon as practicable after receipt of the request or requests of any Holder or Holders. If, however, the Company shall furnish to the Holder or Holders requesting a registration statement pursuant to this Section 4 a certificate
signed by the President of the Company stating that, in the good faith judgment of the Board, it would be seriously detrimental to the Company and its stockholders for such registration statement to be filed and it is therefore essential to defer
the filing of such registration statement, the Company shall have the right to defer such filing within any 12-month period, once for a period of not more than one hundred-twenty (120) days and once for a
period of not more than ninety (90) days after receipt of the request of the Holders initiating registration under this Section 4; provided, however, that the Company may not exercise its second right to defer such filing unless thirty
days have elapsed after the end of the Company’s first such deferral and the registration statement so deferred has been filed. 
 (b)
Underwriting. If the Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request and the Company shall include such information
in its written notice to the other Holders. The right of any Holder to registration pursuant to this Section 4 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable
Securities in the underwriting to the extent provided herein. 
 The Company shall (together with all Holders proposing to distribute their
securities through such underwriting) enter into an underwriting agreement in customary form with the managing underwriter selected for such underwriting by the holders of a majority of the Registrable Securities proposed by such Holders to be
distributed through such underwriting. Notwithstanding any other 

  
 -5- 

 
provision of this Section 4, if the managing underwriter advises the Holders in writing that marketing factors require a limitation of the number of shares to be underwritten, then, subject to
the provisions of Section 4(a) above, the Company shall so advise all Holders and the number of shares of Registrable Securities that may be included in the registration and underwriting shall be allocated among all Holders requesting inclusion in
the registration in proportion, as nearly as practicable, to the respective amounts of Registrable Securities originally requested by such Holders to be included in the Registration Statement. No Registrable Securities excluded from the
underwriting by reason of the managing underwriter’s marketing limitation shall be included in such registration. 
 If the managing
underwriter has not limited the number of Registrable Securities to be underwritten, the Company may include securities for its own account or for the account of others in such registration if the underwriter so agrees and if the number of
Registrable Securities which would otherwise have been included in such registration and underwriting will not thereby be limited, and provided that the Company or the other selling stockholders shall bear an equitable share of the
Registration Expenses in connection with such registration and underwriting. 
 If any Holder of Registrable Securities disapproves of the
terms of the underwriting, such Holder may, subject to Section 7 hereof, elect to withdraw therefrom by written notice to the Company, the managing underwriter and the other Holders. The Registrable Securities and/or other securities so withdrawn
shall also be withdrawn from registration; provided, however, that if by the withdrawal of such Registrable Securities a greater number of Registrable Securities held by other Holders may be included in such registration (up to the
maximum of any limitation imposed by the underwriters), then the Company shall offer to all Holders who have included Registrable Securities in the registration the right to include additional Registrable Securities in the same proportion used in
determining the underwriter limitation in this Section 4(b). 
 5. Company Registration. 

(a) Notice of Registration. If the Company shall determine to register any of its securities, either for its own account or the account
of a security holder or holders exercising their respective demand registration rights (other than under Section 4 hereof), other than: (i) a registration relating solely to employee benefit plans; (ii) a registration relating to
the offer and sale of debt securities; (iii) a registration relating to a corporate reorganization or other transaction on Form S-4; or (iv) a shelf registration statement on Form S-3 for the primary
issuance of securities by the Company pursuant to Rule 415 of the Securities Act, the Company will: 
 (A) promptly give to each Holder
written notice thereof; and 
 (B) include in such registration (and any related qualification under blue sky laws or other
compliance), and in any underwriting involved therein, all the Registrable Securities specified in a written request or requests, made within 15 days after receipt of such written notice from the Company, by any Holder or Holders (a
“piggyback” registration). 
 (b) Cut-Back and Allocation. Notwithstanding any other provision of this Section 5, if
the managing underwriter determines that marketing factors require a limitation of the number of shares to be underwritten, the managing underwriter may limit the number of Registrable 

  
 -6- 

 
Securities to be included in the registration and underwriting; provided, however, that any such limitation shall be restricted so as (i) not to prevent the Holders of Registrable
Securities requesting to be included in such registration from including Registrable Securities representing up to 30% of the total number of shares registered thereby, except for a registration relating to the Company’s initial public offering
of its Common Stock or if the registration was initiated by selling stockholders other than Holders of Registrable Securities pursuant to a registration rights agreement with the Company (which shall, in all cases, be subject to Section 20(a)
hereof), in which cases all Registrable Securities may be excluded (as described in the following subsection) (it being understood that other than in the circumstances described in clauses (ii)(A) and (B) below and the Company’s initial public
offering of its Common Stock, in no case shall the number of securities requested to be included in the registration by the Holders of Registrable Securities be excluded without first excluding shares requested to be included by any other party);
and (ii) (A) if the registration was initiated by selling stockholders other than Holders of Registrable Securities pursuant to a registration rights agreement with the Company (which shall, in all cases, be subject to Section 20(a) hereof) then (1)
all securities requested to be included by the Holders and all other selling stockholders other than the parties to such registration rights agreement shall be excluded pro rata from the registration (provided, however, that the
Registrable Securities requested to be registered by the Holders shall not represent less than 30% of the total number of shares registered thereby unless all shares to be issued by the Company and registered thereby have first been excluded), (2)
thereafter if additional shares must be excluded from such registration, shares to be issued by the Company shall be excluded and (3) thereafter, if additional shares must be excluded from such registration, all selling stockholders party to such
registration rights agreement shall share pro rata in the number of shares to be excluded from such registration pursuant to this clause (ii)(A)(3), such sharing to be based on the respective numbers of shares owned by such holders; and (B) if the
registration was initiated by the Company then, (1) all securities requested to be included by selling stockholders other than Holders of Registrable Securities shall share pro rata in the number of shares to be excluded from such registration, such
sharing to be based on the respective numbers of shares owned by each stockholder, (2) thereafter if additional shares must be excluded from such registration, all securities requested to be included by Holders of Registrable Securities shall share
pro rata in the number of shares to be excluded from such registration, such sharing to be based on the respective number of shares owned by each Holder of Registrable Securities who has elected to participate in such registration, and (3)
thereafter if additional shares must be excluded from such registration, shares to be issued by the Company shall be excluded. In such event, the Company shall so advise all Holders of Registrable Securities which would otherwise be registered and
underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the registration and underwriting shall be allocated among the Holders in proportion, as nearly as practicable, to the respective amounts of
Registrable Securities requested by such Holders. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the managing underwriter. Any Registrable Securities
excluded or withdrawn from such underwriting shall be withdrawn from such registration. 
 (c) Right to Terminate Registration. The
Company shall have the right to terminate or withdraw any registration initiated by it under this Section 5 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. 

  
 -7- 

 6. Registration on Form S-3. The Company shall use its best efforts to qualify for
registration on Form S-3, and to that end, the Company shall comply with the reporting requirements of the Exchange Act. After the Company has qualified for the use of Form S-3, any Holder or group of Holders
of Registrable Securities shall have the right to request that the Company register such Holder’s shares of Registrable Securities on Form S-3 (such requests shall be in writing and shall state the number of shares of Registrable Securities to
be disposed of and the intended method of disposition of such shares by each such Holder), subject to the following limitations: 
 (a) the
Company shall not be obligated to cause a registration on Form S-3 to become effective prior to 60 days following the effective date of a Company-initiated registration (other than a registration effected solely to qualify an employee benefit plan
or to effect a business combination pursuant to Rule 145); 
 (b) the Company shall not be obligated to cause a registration on Form
S-3 to become effective prior to expiration of 90 days following the effective date of the most recent registration pursuant to a request under Section 4 of this Agreement or pursuant to a request by a holder of registration rights under any other
agreement of the Company granting Form S-3 demand registration rights that has been approved in accordance with Section 20(a) hereof; 
 (c)
the Company shall not be required to effect more than three (3) registrations on Form S-3 pursuant to this Section 6 during any 12-month period; 

(d) the Company shall not be required to effect a registration on Form S-3 unless the Holder or Holders requesting registration propose to
dispose of shares of Registrable Securities having an aggregate anticipated gross offering price to the public (before deduction of underwriting discounts and expenses of sale) of at least $3,000,000; 

(e) the Company shall not be required to maintain and keep any such registration on Form S-3 effective after the earlier to occur of (A) 90
days from the date of effectiveness of such registration statement or (B) such date as the disposition of the Registrable Securities subject to such registration has been completed; and 

(f) if the Company shall furnish to the Holder or Holders requesting a registration statement pursuant to this Section 6 a certificate signed
by the President of the Company stating that, in the good faith judgment of the Board, it would be seriously detrimental to the Company and its stockholders for such registration statement to be filed, and it is therefore essential to defer the
filing of such registration statement, the Company shall have the right to defer such filing within any 12-month period, once for a period of not more than one hundred-twenty (120) days and once for a period of not more than ninety (90) days after
receipt of the request of the Holders initiating registration under this Section 6; provided, however, that the Company may not exercise its second right to defer such filing unless thirty days have elapsed after the end of the
Company’s first such deferral and the registration statement so deferred has been filed. 
 The Company shall give notice to all
Holders of the receipt of a request for registration pursuant to this Section 6 and shall provide a reasonable opportunity for all such other Holders to participate in the registration. Subject to the foregoing, the Company will use its best efforts
to effect promptly the registration of all shares of Registrable Securities on Form S-3 to the extent requested by the Holder or Holders thereof for purposes of disposition. 

  
 -8- 

 7. Expenses of Registration. All Registration Expenses incurred in connection with any
registration, qualification or compliance pursuant to Sections 4, 5, or 6 hereof shall be borne by the Company. All Selling Expenses relating to securities registered by the Holders shall be borne by the Holders of such securities pro rata on the
basis of the number of shares so registered. Notwithstanding the foregoing, the Company shall not be required to pay for Registration Expenses pursuant to Section 4 if the registration request is subsequently withdrawn at the request of the
Holders of a majority of the Registrable Securities to be registered (which Holders shall bear such expenses), unless the holders of a majority of the Registrable Securities to be registered agree to forfeit one demand registration right pursuant to
Section 4; provided, however, that if at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business or prospects of the Company from that known to the Holders at the time of their
request, then the Holders shall not be required to pay any of such Registration Expenses and shall not forfeit their right to one demand registration pursuant to Section 4. If the Company shall withdraw a registration initiated under
Section 5, the expenses of such withdrawn registration shall be borne by the Company. 
 8. Registration Procedures. In the case
of each registration, qualification, or compliance effected by the Company pursuant to this Agreement, the Company will keep each Holder advised in writing as to the initiation of each registration, qualification, and compliance and as to the
completion thereof. In connection with any registration effected pursuant to this Agreement, the Company will prepare and file such amendments and supplements to its registration statement as may be necessary to comply with the provisions of the
Securities Act with respect to the disposition of all securities covered by such registration statement. At its expense the Company will furnish such number of prospectuses and other documents incident thereto as a Holder from time to time may
reasonably request. In connection with any registration effected pursuant to this Agreement, the Company shall also (to the extent not otherwise expressly required pursuant to this Agreement): 

(a) Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective; 
 (b) Use its commercially reasonable efforts to register and qualify the
securities covered by such registration statement under such other securities or blue sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided, however, that the Company shall not be required in
connection therewith or as a condition thereto, to qualify to do business or to file a general consent to service of process in any such states or jurisdictions; and 

(c) Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is
required to be delivered under the Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact
required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. The Company will use reasonable efforts to amend or supplement such prospectus in order to cause such
prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 

  
 -9- 

 (d) Furnish to the Holders such number of copies of a prospectus, including a preliminary
prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 

(e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter(s) of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 

(f) Use its reasonable efforts to furnish, on the date that such Registrable Securities are delivered to the underwriters for sale, if such
securities are being sold through underwriters, (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an
underwritten public offering, addressed to the underwriters, if any, and (ii) a letter, dated as of such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent
certified public accountants to underwriters in an underwritten public offering addressed to the underwriters. 
 9. Termination of
Registration Rights. The registration rights granted pursuant to this Agreement shall terminate five years after the close of the Company’s initial public offering or, as to any Holder, at such time after the Company’s initial public
offering as the Registrable Securities held by such Holder may be sold within any three-month period without restriction pursuant to Rule 144 promulgated under the Securities Act, at which time, the Registrable Securities held by such Holder will
not be considered “then outstanding shares of Registrable Securities” and the consent of such Holder shall not be counted for purposes of obtaining the majority consent required for purposes of amending this Agreement pursuant to
Section 19. 
 10. Lock-up Agreement. In consideration for the Company agreeing to its obligations under this Agreement, each
Holder of Registrable Securities and each transferee pursuant to Section 15 hereof agrees, in connection with the first registration of the Company’s securities under the Securities Act, upon request of the Company or the underwriters
managing any underwritten offering of the Company’s securities, not to (a) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to
purchase or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (whether such shares or any such securities are then owned by the
Holder or are thereafter acquired) or (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause
(a) or (b) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise, without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed
180 days or such other period as may be 

  
 -10- 

 
requested by the Company or the underwriters to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and
opinions, including, but not limited to, the restrictions contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto) from the effective date of such registration as the Company or the underwriters
may specify; provided, however, that all (x) officers and directors of the Company and (y) stockholders of the Company holding three percent (3%) or more of the total outstanding Common Stock of the Company (treating all
convertible, exercisable and exchangeable Company securities on an as-if converted to Common Stock basis) are bound by agreements that are no less restrictive. The underwriters in connection with the Company’s initial public offering are
intended third party beneficiaries of this Section 10 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder agrees that the Company may instruct its transfer agent to
place stop-transfer notations in its records to enforce the provisions of this Section 10 until the end of such period. This Section 10 shall supersede any conflicting provision of Section 4 or Section 6 above. 

11. Restrictive Legend. Each certificate representing (a) the Preferred, (b) shares of the Common Stock issued upon
conversion of the Preferred, (c) any security for which subsequent registration rights are granted in accordance with Section 20(b) of the Agreement, and (d) any other securities issued in respect of any shares described in clauses (a),
(b), and (c) above upon any stock split, stock dividend, recapitalization, or similar event, shall (unless otherwise permitted by the provisions of Section 3 above) be stamped or otherwise imprinted with a legend in substantially the
following form (in addition to any legend required under applicable state securities laws): 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THESE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR TRANSFERRED UNLESS (I) THERE IS AN EFFECTIVE
REGISTRATION STATEMENT COVERING SUCH OFFER, SALE OR TRANSFER OR (II) THERE IS AN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE COMPANY, THAT AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT FOR SUCH OFFER, SALE OR TRANSFER
IS AVAILABLE. COPIES OF THE AGREEMENTS COVERING THE PURCHASE OF THESE SECURITIES AND RESTRICTING THEIR TRANSFER MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY AT ITS
PRINCIPAL EXECUTIVE OFFICES. 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD OF UP TO 180 DAYS FOLLOWING
THE EFFECTIVE DATE OF A REGISTRATION STATEMENT OF THE COMPANY FILED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE
PRINCIPAL OFFICE OF THE COMPANY. SUCH LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE SECURITIES. 

  
 -11- 

 Each Purchaser and Holder consents to the Company making a notation on its records and giving
instructions to any transfer agent of the Preferred or the Common Stock in order to implement the restrictions on transfer established in this Section. 

12. Indemnification. 
 (a)
To the extent permitted by law, the Company will indemnify each Holder, each of its officers, directors and partners and such Holder’s legal counsel and independent accountants, and each person controlling such Holder within the meaning of
Section 15 of the Securities Act, with respect to which registration, qualification or compliance has been effected pursuant to this Agreement, and each underwriter, if any, and each person who controls any underwriter within the meaning of
Section 15 of the Securities Act, against all expenses, claims, losses, damages and liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened, arising out of or
based on any untrue statement (or alleged untrue statement) of a material fact contained in any registration statement, prospectus, offering circular or other document, or any amendment or supplement thereto, incident to any such registration,
qualification or compliance, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not
misleading, or any violation or alleged violation by the Company of the Securities Act or the Exchange Act or the securities laws of any state or any rule or regulation thereunder, and relating to action or inaction required of the Company in
connection with any such registration, qualification or compliance, and will reimburse each such Holder, each of its officers, directors and partners and such Holder’s legal counsel and independent accountants, and each person controlling such
Holder, each such underwriter and each person who controls any such underwriter, for any legal and any other expenses reasonably as incurred in connection with investigating, preparing or defending any such claim, loss, damage, liability or action;
provided, however, that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability or expense arises out of or is based on any untrue statement or omission or alleged untrue statement or
omission, made in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by such Holder or underwriter and stated to be specifically for use therein; and provided further, that
the Company will not be liable to any such person or entity with respect to any such untrue statement or omission or alleged untrue statement or omission made in any preliminary prospectus that is corrected in the final prospectus filed with the
Commission pursuant to Rule 424(b) promulgated under the Securities Act (or any amendment or supplement to such prospectus) if the person asserting any such loss, claim, damage or liability purchased securities but was not sent or given a copy of
the prospectus (as amended or supplemented) at or prior to the written confirmation of the sale of such securities to such person in any case where such delivery of the prospectus (as amended or supplemented) is required by the Securities Act,
unless such failure to deliver the prospectus (as amended or supplemented) was a result of the Company’s failure to provide such prospectus (as amended or supplemented). 

  
 -12- 

 (b) To the extent permitted by law, each Holder will, severally and not jointly, if Registrable
Securities held by such Holder are included in the securities as to which such registration, qualification or compliance is being effected, indemnify the Company, each of its directors and officers and its legal counsel and independent accountants,
each underwriter, if any, of the Company’s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, and each other such Holder,
each of its officers, directors and partners and each person controlling such Holder within the meaning of Section 15 of the Securities Act, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or
based on any untrue statement (or alleged untrue statement) of a material fact contained in any such registration statement, prospectus, offering circular or other document, or any omission (or alleged omission) to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company, such other Holders, such directors, officers, legal counsel, independent accountants, underwriters or control persons for any
legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue
statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed
by such Holder and stated to be specifically for use therein; provided, however, that the obligations of such Holders hereunder shall be limited to an amount equal to the proceeds, net of underwriting discounts and commissions but not
expenses, to each such Holder of Registrable Securities sold as contemplated herein. 
 (c) Each party entitled to indemnification under this
Section 12 (the “Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to
which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom; provided, however, that counsel for the Indemnifying Party, who shall conduct the
defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld) and the Indemnified Party may participate in such defense at such Indemnified Party’s expense; and
provided further, that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Agreement, except to the extent, but only to the extent, that the
Indemnifying Party’s ability to defend against such claim or litigation is impaired as a result of such failure to give notice. No Indemnifying Party in the defense of any such claim or litigation shall, except with the consent of each
Indemnified Party, which consent shall not be unreasonably withheld, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified
Party of a release from all liability in respect to such claim or litigation. 
 (d) If the indemnification provided for in this
Section 12 is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage or expense referred to therein, then the Indemnifying Party, in lieu of indemnifying such
Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the
Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations,

  
 -13- 

 
provided, however, that the obligations of such Holders hereunder shall be limited to an amount equal to the proceeds, net of underwriting discounts and commissions but not
expenses, to each such Holder of Registrable Securities sold as contemplated herein. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or the omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the Parties’ relative intent, knowledge, access to information and
opportunity to correct or prevent such statement or omission. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on
indemnification and contribution contained in the underwriting agreement entered into in connection with an underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) The obligations of the Company and Holders under this Section 12 shall survive the completion of any offering of Registrable
Securities in a registration statement under this Agreement and the termination of this Agreement. 
 13. Information by Holder. The
Holder or Holders of Registrable Securities included in any registration shall furnish to the Company such information regarding such Holder or Holders and the distribution proposed by such Holder or Holders as the Company may request in writing and
as shall be required in connection with any registration, qualification or compliance referred to in this Agreement. 
 14. Rule 144
Reporting. With a view to making available the benefits of certain rules and regulations of the Commission which may at any time permit the sale of the Restricted Securities to the public without registration, after such time as a public market
exists for the Common Stock, the Company agrees to use its best efforts to: 
 (a) make and keep public information available, as those terms
are understood and defined in Rule 144 promulgated under the Securities Act, at all times after the effective date of the first registration under the Securities Act filed by the Company for an offering of its securities to the general public; 

(b) file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the
Exchange Act (at any time after it has become subject to such reporting requirements); and 
 (c) furnish to Holders upon request a written
statement as to its compliance with the reporting requirements of Rule 144 (at any time after 90 days after the effective date of the first registration statement filed by the Company for an offering of its securities to the general public), and of
the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents of the Company as a Holder
may reasonably request in availing itself of any rule or regulation of the Commission allowing such Holder to sell any such securities without registration. 

  
 -14- 

 15. Transfer of Rights. The rights granted hereunder to cause the Company to register
securities may be assigned to (a) a transferee or assignee of Purchaser who acquires at least 200,000 shares of Common Stock and/or shares of the Company’s Preferred Stock convertible into such number of shares of Common Stock, and
(b) any Affiliate of a Purchaser, provided that, in either case, (i) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the
securities with respect to which such registration rights are being assigned; (ii) such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement, including, without limitation, the
provisions of Section 10 hereof; and (iii) such assignment shall be effective only if immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Securities Act. 

16. Governing Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of California, as
applied to agreement entered and to be performed entirely within California. 
 17. Entire Agreement. This Agreement and any other
agreement entered into by the Company and any other party hereto in connection herewith constitute the full and entire understanding among the parties regarding the subject matter herein. Except as otherwise expressly provided herein, the provisions
hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto. 

18. Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered
or certified mail, postage prepaid, or otherwise delivered by hand or by messenger, addressed (a) if to a Holder, to such Holder’s address as set forth in the books and records of the Company or to such other address as such Holder shall
have furnished to the Company in writing; (b) if to any other person or entity who may become a Holder pursuant to this Agreement, to such address as such person or entity shall have furnished the Company in writing, or, until any such
purchaser or entity so furnishes an address to the Company, then to the address of the last holder of such Registrable Securities who has so furnished an address to the Company; (c) if to the Company, to its principal executive offices, located
at 1252 Orleans Drive, Sunnyvale, California 94089, and addressed to the attention of the Chief Executive Officer, or to such other address as the Company shall have furnished to the other parties hereto. 

Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given when delivered
if delivered personally, or, if sent by mail, at the earlier of its receipt or 72 hours after the same has been deposited in a regularly maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid. 

19. Amendment. Any provision of this Agreement may be amended, waived or modified upon the written consent of (a) the Company and
(b) holders of a majority of the then outstanding shares of Registrable Securities held by the original signatories (and their permitted transferees and assignees) of this Agreement; provided, however, that investors purchasing
shares of the Company’s Series G Preferred Stock in a closing that occurs on or subsequent to the date hereof may become parties to this Agreement by executing a counterpart of this Agreement without any amendment of this Agreement pursuant to
this paragraph or any consent or approval of any other Holder; provided, 

  
 -15- 

 
further, the foregoing notwithstanding, the rights of any individual holder of Registrable Securities shall not be amended or waived without the prior written consent of such holder if
such amendment or waiver (a) is adverse to such holder in a manner that differs from how similarly situated holders of Registrable Securities are affected or (b) reduces or alters the rights of any Holder vis-à-vis any other Holder.
Any Holder may waive any of his or her rights or the Company’s obligations hereunder without obtaining the consent of any other Holder. 

20. Limitations on Subsequent Registration Rights. 

(a) From and after the date of this Agreement, the Company shall not enter into any agreement granting any holder or prospective holder of any
securities of the Company registration rights with respect to such securities without the prior written consent of the holders of a majority of the Registrable Securities then outstanding unless (i) such new registration rights are piggyback
registration rights that are subordinate in all respects to those granted to the original signatories to this Agreement pursuant to Section 5 of this Agreement, and (ii) such holder or prospective holder agrees to a standoff obligations
provision no less restrictive than the one set forth in Section 10 hereof. 
 (b) Where the Company determines to grant any holder or
prospective holder of any securities of the Company piggyback registration rights (in connection with the original issuance of the securities to which such rights relate) that are subordinate in all respects to those of the original signatories to
this Agreement hereunder and determines that the grant of such rights shall be made pursuant to this Agreement, then such grant shall be evidenced by the execution of an additional signature page to this Agreement by the Company and such holder,
without any requirement on the part of the Company to seek any consent or approval of the Holders and the shares of the Company’s Common Stock issued or issuable to such holder shall be deemed Registrable Securities hereunder and such holder
shall be deemed a Purchaser for purposes of this Agreement. 
 (c) Notwithstanding the foregoing, each of the Holders acknowledges and agrees
that the Company has granted certain registration rights to Venture Lending & Leasing III, LLC, a Delaware limited liability company (“VL&L”), pursuant to the Registration Rights Agreement dated as of May 3, 2002,
as amended pursuant to Amendment No. 1 thereto dated as of September 13, 2002 (the “First Amendment”) and Amendment No. 2 thereto dated as of April 18, 2003 (the “Second Amendment”). In
accordance with the First Amendment and the Second Amendment, each of the Holders agrees that VL&L shall be deemed a “Holder” for all purposes of this Agreement with respect to the Registrable Securities issuable upon exercise of the
Warrants (as each individual “Warrant” is defined in the First Amendment and the Second Amendment); provided, however, (i) VL&L shall have no rights under Section 4 of this Agreement and
(ii) Section 15 of this Agreement, which sets forth restrictions on the transfer of the rights set forth herein, shall not apply to VL&L. 

(d) Notwithstanding the foregoing, each of the Holders acknowledges and agrees that the Company has granted certain registration rights to
TriplePoint Capital LLC, a Delaware limited liability company (“TriplePoint”), pursuant to Amendment No. 1 to the Seventh Amended and Restated Registration Rights Agreement dated as of October 29, 2010 (the “First
Amendment”). 

  
 -16- 

 In accordance with the First Amendment, each of the Holders agrees that TriplePoint shall be deemed a
“Holder” for all purposes of this Agreement with respect to the Registrable Securities issuable upon exercise of the TriplePoint Warrant(s) (as defined in the First Amendment); provided, however, that TriplePoint shall have no rights under
Section 4 of this Agreement. 
 21. Aggregation. For the purposes of this Agreement, the number of shares of Registrable
Securities held by a Holder shall include the holdings of its Affiliates, and such holdings shall be aggregated together. 
 22.
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original and all of which together shall constitute one instrument. 

23. Telecopy Execution and Delivery. A facsimile, telecopy or other reproduction of this Agreement may be executed by one or more
parties hereto, and an executed copy of this Agreement may be delivered by one or more parties hereto by facsimile or similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen, and such
execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute an original of this Agreement as well as any facsimile, telecopy or other reproduction
hereof. 
 24. Jurisdiction; Venue. With respect to any disputes arising out of or related to this Agreement, the parties consent to
the exclusive jurisdiction of, and venue in, the state courts in Santa Clara County in the State of California (or in the event of exclusive federal jurisdiction, the courts of the Northern District of California). 

25. Waiver of Potential Conflicts of Interest. Each of the Holders and the Company acknowledges that Wilson Sonsini Goodrich &
Rosati, Professional Corporation (“WSGR”) may have represented and may currently represent such Holder and other Holders in matters unrelated to the transactions contemplated by this Agreement. In the course of such representation,
WSGR may have come into possession of confidential information relating to such Holders. Each of the Holders and the Company acknowledges that WSGR is representing only the Company in this transaction. Each of the Holders and the Company understands
that an affiliate of WSGR is a Holder under this Agreement. Pursuant to Rule 3-310 of the Rules of Professional Conduct promulgated by the State Bar of California, an attorney must avoid representations in which the attorney has or had a
relationship with another party interested in the representation without the informed written consent of all parties affected. By executing this Agreement, each of the Holders and the Company hereby waives any actual or potential conflict of
interest that may arise in this financing as a result of WSGR’s representation of such persons or entities in the financing, WSGR’s possession of such confidential information and the rights of WSGR’s affiliate as a Holder under this
Agreement. Each of the Holders and the Company represents that it has had the opportunity to consult with independent counsel concerning the giving of this waiver. 

26. Adjustments for Stock Splits, Etc. Wherever in this Agreement there is a reference to a specific number of shares of Common Stock
or Preferred Stock of the Corporation of any class or series, then, upon the occurrence of any subdivision, combination or stock dividend of such class or series of stock, the specific number of shares so referenced in this Agreement shall
automatically be proportionately adjusted to reflect the affect on the outstanding shares of such class or series of stock by such subdivision, combination or stock dividend. 

  
 -17- 

 27. Costs And Attorneys’ Fees. In the event that any action, suit or other proceeding
is instituted concerning or arising out of this Agreement or any transaction contemplated hereunder, the prevailing party shall recover all of such party’s costs and attorneys’ fees incurred in each such action, suit or other proceeding,
including any and all appeals or petitions therefrom. 
 28. Amendment and Restatement. This Agreement amends and restates in its
entirety the Prior Registration Agreement. In accordance with Section 19 of the Prior Registration Agreement, this Agreement shall be effective when executed by the Company and holders of a majority of the outstanding shares of Registrable
Securities held by the original signatories (and their permitted transferees and assignees) of the Prior Registration Agreement. 

[Remainder of Page Intentionally Left Blank] 

  
 -18- 

 IN WITNESS WHEREOF, the undersigned have executed this Eighth Amended and Restated Registration
Rights Agreement as of the date set forth above. 
  

							
	“COMPANY”	 		 	BLOOM ENERGY CORPORATION
		 		 	a Delaware corporation
				
		 		 	By:	 	/s/ K.R. Sridhar
		 		 		 	  

		 		 		 	K.R. Sridhar
		 		 		 	President and Chief Executive Officer
			
	“PURCHASERS”	 		 	K.R. SRIDHAR
				
		 		 	Signature:	 	/s/ K.R. Sridhar
		 		 		 	  

		 		 	Address:	 	 18351 Overlook Road
 Los Gatos, CA
95030

  
 [Signature Page to
Bloom Energy Eighth Amended and Restated Registration Rights Agreement] 

 IN WITNESS WHEREOF, the undersigned have executed this Eighth Amended and Restated Registration
Rights Agreement as of the date set forth above. 
  

					
	“PURCHASERS”	 	1536057 ALBERTA LTD.
			
		 	By:	 	/s/ Jagdeep Singh Bachher
		 		 	  

		 	Name:	 	Jagdeep Singh Bachher
		 	Title:	 	Director
		
		 	1536053 ALBERTA LTD.
			
		 	By:	 	/s/ Jagdeep Singh Bachher
		 		 	  

		 	Name:	 	Jagdeep Singh Bachher
		 	Title:	 	Director

  
 [Signature Page to
Bloom Energy Eighth Amended and Restated Registration Rights Agreement] 

 IN WITNESS WHEREOF, the undersigned have executed this Eighth Amended and Restated Registration
Rights Agreement as of the date set forth above. 
  

							
	“PURCHASERS”	 		 	KPCB HOLDINGS, INC., as nominee
				
		 		 	By:	 	/s/ John Doerr
		 		 		 	  

		 		 	Name:	 	John Doerr
		 		 	Title:	 	President
		 		 	Address:	 	 2750 Sand Hill Road
 Menlo Park, CA
94025

  
 [Signature Page to
Bloom Energy Eighth Amended and Restated Registration Rights Agreement] 

 IN WITNESS WHEREOF, the undersigned have executed this Eighth Amended and Restated Registration
Rights Agreement as of the date set forth above. 
  

							
	“PURCHASERS”	 		 	 NEW ENTERPRISE ASSOCIATES 10,

LIMITED PARTNERSHIP

				
		 		 	By:	 	 NEA Partners 10, Limited Partnership
 its
General Partner

				
		 		 	By:	 	/s/ Louis S. Citron
		 		 		 	  

		 		 		 	Chief Legal Officer
				
		 		 	Name:	 	Louis S. Citron
		 		 	Address:	 	 1954 Greenspring Dr,
 Suite 600

		 		 		 	Timonium, MD 21093
		 		 		 	
		 		 	NEA VENTURES 2003, LIMITED PARTNERSHIP
				
		 		 	By:	 	/s/ Louis S. Citron
		 		 		 	  

		 		 		 	Chief Legal Officer
				
		 		 	Name:	 	Louis S. Citron
		 		 	Address:	 	 1954 Greenspring Dr,
 Suite 600

Timonium, MD 21093

  
 [Signature Page to
Bloom Energy Eighth Amended and Restated Registration Rights Agreement] 

 IN WITNESS WHEREOF, the undersigned have executed this Eighth Amended and Restated Registration
Rights Agreement as of the date set forth above. 
  

							
	“PURCHASERS”	 		 	MORGAN STANLEY PRINCIPAL INVESTMENT, INC.
				
		 		 	By:	 	 /s/ Thomas E. Doster IV

 

		 		 	Name:	 	Thomas E. Doster IV
		 		 	Title:	 	Managing Director
		 		 	Address:	 	 1585 Broadway
 NY, NY 10036

  

  
 [Signature Page to
Bloom Energy Eighth Amended and Restated Registration Rights Agreement] 

 IN WITNESS WHEREOF, the undersigned have executed this Eighth Amended and Restated Registration
Rights Agreement as of the date set forth above. 
  

									
	“PURCHASERS”	 		 	MOBIUS TECHNOLOGY VENTURES VI L.P.
				
		 		 		 	SOFTBANK U.S. VENTURES VI L.P.
		 		 		 	 MOBIUS TECHNOLOGY VENTURES

    ADVISORS FUND VI L.P.

		 		 		 	 MOBIUS TECHNOLOGY VENTURES

    SIDE FUND VI L.P.

				
		 		 		 	By: Mobius VI LLC, General Partner
					
		 		 		 	By:	 	/s/ Jason A. Mendelson
		 		 		 		 	  

		 		 		 	Name:	 	Jason A. Mendelson
		 		 		 	Title:	 	Managing Director
		 		 		 	Address:	 	1050 Walnut Street, Suite 210
		 		 		 		 	Boulder, CO 80302

  
 [Signature Page to
Bloom Energy Eighth Amended and Restated Registration Rights Agreement] 

 IN WITNESS WHEREOF, the undersigned have executed this Eighth Amended and Restated Registration
Rights Agreement as of the date set forth above. 
  

							
	“PURCHASERS”	 		 	TJ RODGERS
				
		 		 	By:	 	 /s/ TJ RODGERS

  

  
 [Signature Page to
Bloom Energy Eighth Amended and Restated Registration Rights Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]